J Korean Ophthalmol Soc.  2014 Jul;55(7):1056-1063.

The Effect of Fixed Combination of Brinzolamide 1% and Timolol 0.5% in Normal-Tension Glaucoma

• Park HS
• Choi CY
• Bae JH
• Kim JM

Abstract

PURPOSE
We conducted a study to evaluate the effects of brinzolamide/timolol fixed combination (BTFC) in normal-tension glaucoma (NTG) patients.
METHODS
We reviewed the records of 33 normal-tension glaucoma patients treated with BTFC in the unilateral eye. We measured intraocular pressure (IOP) every 2 and 1/2 hours between 09:00 am and 04:30 pm. After using BTFC at 8:00 am and 8:00 pm for 6 months, we measured the IOP at the same time period. We analyzed and compared the IOP of eyes treated with BTFC and contralateral eyes.
RESULTS
The mean reduction in IOP was -2.85 +/- 1.43 mm Hg (-18.36 +/- 8.58%) in the eyes treated with BTFC and -2.21 +/- 1.73 mm Hg (-13.90 +/- 10.66%) in the contralateral eyes. The IOP lowering effect was greater in the eyes treated with BTFC than in the contralateral eyes. After 6 months of BTFC instillation, the changes in IOP measurements were the lowest at 11:30 am and increased at each time point afterwards. The greatest reduction in IOP was observed at 1 month; however, significant IOP reduction was observed at 3 and 6 months in both BTFC and contralateral eyes. There was no serious adverse event causing ocular damage.
CONCLUSIONS
BTFC provided a significant IOP reduction in both BTFC and contralateral eyes in NTG patients.

Keyword

Brinzolamide; Fixed combination; Intraocular pressure; Normal-tension glaucoma; Timolol

MeSH Terms

Glaucoma*
Humans
Intraocular Pressure
Timolol*
Timolol

Figure

• 

  Figure 1. Diurnal intraocular pressure of Brinz/Tim eye and contralateral eye at baseline and month 6. Brinz/Tim = brinzolamide 1% + timolol 0.5% eye drops.

• 

  Figure 2. Mean intraocular pressure of Brinz/Tim eye and contralateral eye at each visit point. Brinz/Tim = brinzolamide 1% + timolol 0.5% eye drops.

Reference

References

1. Schulzer M. Intraocular pressure reduction in normal-tension glaucoma patients. The Normal Tension Glaucoma Study Group. Ophthalmology. 1992; 99:1468–70.

2. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120:1268–79.

3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120:701–13. discussion 829-30.

4. Sacca SC, Rolando M, Marietta A, et al. Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma and normal subjects. Ophthalmologica. 1998; 212:115–9.

5. De Vivero C, O'Brien C, Lanigan L, Hitchings R. Diurnal intraocular pressure variation in low-tension glaucoma. Eye (Lond). 1994; 8(Pt 5):521–3.

6. David R, Zangwill L, Briscoe D, et al. Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br J Ophthalmol. 1992; 76:280–3.

7. Kano K, Kuwayama Y. Diurnal variation of intraocular pressure in normal-tension glaucoma. Nihon Ganka Gakkai Zasshi. 2003; 107:375–9.

8. Wilensky JT, Gieser DK, Dietsche ML, et al. Individual variability in the diurnal intraocular pressure curve. Ophthalmology. 1993; 100:940–4.

9. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108:1943–53.

10. Bron A, Baudouin C, Denis P, et al. Satisfaction and compliance of ocular hypertensive and glaucoma patients topically treated with a combination therapy. J Fr Ophtalmol. 2008; 31:659–65.

11. Anderson DR, Drance SM, Schulzer M. Natural history of normal-tension glaucoma. Ophthalmology. 2001; 108:247–53.

12. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998; 126:487–97.

13. Cartwright MJ, Anderson DR. Correlation of asymmetric damage with asymmetric intraocular pressure in normal-tension glaucoma (low-tension glaucoma). Arch Ophthalmol. 1988; 106:898–900.

14. Crichton A, Drance SM, Douglas GR, Schulzer M. Unequal intraocular pressure and its relation to asymmetric visual field defects in low-tension glaucoma. Ophthalmology. 1989; 96:1312–4.

15. Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008; 115:1728–34. 34 e1-2.

16. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzo- lamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009; 18:293–300.

17. Oh JY, Park KH. The effect of latanoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Korean J Ophthalmol. 2005; 19:297–301.

18. Cho SW, Kim JM, Park KH, Choi CY. Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma. Jpn J Ophthalmol. 2010; 54:407–13.

19. Suh MH, Park KH, Kim DM. Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol. 2009; 53:18–23.

20. Kim TW, Kim M, Lee EJ, et al. Intraocular Pressure-lowering Efficacy of Dorzolamide/Timolol Fixed Combination in Normal- tension Glaucoma. J Glaucoma. 2014; 23:329–32.

21. Kim NJ, Lee SM, Park KH, Kim DM. Factors associated with pro- gression of visual field defect in normal tension glaucoma. J Korean Ophthalmol Soc. 2003; 44:1351–5.

22. Han ES, Kim MJ, Park KH. The relationship between intraocular pressure and visual field defect progression in normal-tension glaucoma. J Korean Ophthalmol Soc. 2009; 50:1548–54.

23. Jonas JB, Budde W, Stroux A, et al. Single intraocular pressure measurements and diurnal intraocular pressure profiles. Am J Ophthalmol. 2005; 139:1136–7.

24. Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977; 95:601–4.

25. Drance SM. The uniocular therapeutic trial in the management of elevated intraocular pressure. Surv Ophthalmol. 1980; 25:203–5.

26. Kwitko GM, Shin DH, Ahn BH, Hong YJ. Bilateral effects of long-term monocular timolol therapy. Am J Ophthalmol. 1987; 104:591–4.

27. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. GLT Research Group. Ophthalmic Surg. 1991; 22:324–9.

28. Martin XD, Rabineau PA. Intraocular pressure effects of timolol after unilateral instillation. Ophthalmology. 1988; 95:1620–3.

29. Piltz J, Gross R, Shin DH, et al. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol. 2000; 130:441–53.

30. Bartels SP. Aqueous humor flow measured with fluorophotometry in timolol-treated primates. Invest Ophthalmol Vis Sci. 1988; 29:1498–504.

31. Dunham CN, Spaide RF, Dunham G. The contralateral reduction of intraocular pressure by timolol. Br J Ophthalmol. 1994; 78:38–40.

32. Huupponen R, Kaila T, Salminen L, Urtti A. The pharmacokinetics of ocularly applied timolol in rabbits. Acta Ophthalmol (Copenh). 1987; 65:63–6.

33. Lutjen-Drecoll E, Kaufman PL, Eichhorn M. Long-term timolol and epinephrine in monkeys. I. Functional morphology of the ciliary processes. Trans Ophthalmol Soc U K. 1986; 105(Pt 2):180–95.

34. Lutjen-Drecoll E, Kaufman PL. Long-term timolol and epinephrine in monkeys. II. Morphological alterations in trabecular meshwork and ciliary muscle. Trans Ophthalmol Soc U K. 1986; 105(Pt 2):196–207.

35. Saari KM, Ali-Melkkila T, Vuori ML, et al. Absorption of ocular timolol: drug concentrations and beta-receptor binding activity in the aqueous humour of the treated and contralateral eye. Acta Ophthalmol (Copenh). 1993; 71:671–6.

36. Radius RL, Diamond GR, Pollack IP, Langham ME. Timolol. A new drug for management of chronic simple glaucoma. Arch Ophthalmol. 1978; 96:1003–8.

37. Gibbens MV. The consensual ophthalmotonic reaction. Br J Ophthalmol. 1988; 72:746–9.

38. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimo- nidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006; 124:1230–8.